Business Information
The group's principal activities are carried out through two business units, core elan and elan enterprises. Core elan comprises pharmaceutical commercial activities which includes the marketing of products in the therapeutic areas of neurology, pain management and infectious diseases, and biopharmaceutical research and development activities which includes the discovery and development of products in the therapeutic areas of neurology, pain management and auto immune diseases. Elan enterprises comprises drug delivery businesses which includes the development, licensing and marketing of drug delivery products, technologies and services.
|
|
Name |
Title
|
Email
|
| Kyran McLaughlin | Chmn. | N/A | | Dale Schenk | Chief Scientific Officer, Sr. VP | N/A | | Allison Hulme | Exec. VP, Head - Autoimmune, Tysabri Franchise | N/A | | Chris Burns | Sr. VP - Investor Relations | N/A | | David Feigal | Sr. VP, Head - Global Regulatory, Global Safety Surveillance | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 560,400 | (267,300) | | 2005 | 490,300 | (383,600) | | 2004 | 481,700 | (394,700)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
